ClinicalTrials.gg

Program

bemdaneprocel

Also written as “MSK-DA01”.

Its studies are mostly in Parkinson Disease, led by Bayer.

Furthest: phase 3, since Apr 7, 20252 company-led studies, 1 open or runningNext primary completion: Oct 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer21 open or runningphase 3since Apr 7, 2025Mar 12, 2021Oct 2028phase 3 · NCT06944522

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 12, 2021First study: phase 1 study in Advanced Parkinson's DiseaseFirst studyNCT04802733 · 12 enrolled · United States, Canada
  2. Apr 7, 2025Phase 3 study in Parkinson DiseaseNCT06944522 · 102 planned · United States, Australia, Canada
  3. Oct 30, 2026Primary completion moved from 2027-03 to 2028-10Date moved laterphase 3 · +19 months · NCT06944522

Ahead

  1. Oct 2028Primary completion: phase 3 study in Parkinson DiseaseNCT06944522

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06944522Parkinson Disease · United States, Australia, Canada3RecruitingOct 2028102
NCT04802733Advanced Parkinson's Disease · United States, Canada1CompletedMay 18, 202312

How it is read

Names in the registry

  • “bemdaneprocel”, 1 entry
  • “MSK-DA01”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.